Skip to main content
. 2024 Nov 6;16(22):3752. doi: 10.3390/cancers16223752

Figure 8.

Figure 8

Graphical abstract. Using transcriptomics, in vitro models, and network pharmacology, we found that trastuzumab synergizes with the HDAC6-specific inhibitor NexturastatA, probably through the modulation of HSP90, leading to cell death and inhibition of cell proliferation of HER2+ BC cells that are both sensitive and resistant to trastuzumab.